Lakewood-Amedex Biotherapeutics, Inc. (LABT)
NCM · Healthcare · Biotechnology
Closing price as of 2026-06-12 · Source: TEK2day Finance
Key Metrics
About Lakewood-Amedex Biotherapeutics, Inc.
Lakewood-Amedex Biotherapeutics, Inc. operates as a clinical-stage biotechnology company that develops antimicrobial products in the United States. The company offers products from its Bisphosphocin class, a novel class of antimicrobial agents a broad range of infections, including those affecting the skin, bladder, and lungs. It also develops Nu-3, a topical antimicrobial for infected diabetic foot ulcers, which is in Phase 2b clinical trial. The company was formerly known as Lakewood-Amedex Inc. and changed its name to Lakewood-Amedex Biotherapeutics, Inc. in June 2025. Lakewood-Amedex Biotherapeutics, Inc. was incorporated in 2006 and is headquartered in University Park, Florida.
Quarterly Financials
| Metric | 2025-03-31 | 2025-09-30 | 2025-12-31 | 2026-03-31 |
|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Income | -543K | -1.9M | -712K | -887K |
| Net Income | -540K | -1.9M | -745K | -923K |
| Diluted EPS | $-0.15 | $-0.14 | $nan | $-0.20 |
Annual Financials
| Metric | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 |
| Operating Income | -8.6M | -4.0M | -3.8M |
| Net Income | -8.3M | -4.9M | -3.8M |
| Diluted EPS | $-1.18 | $-0.69 | $-0.28 |